Views

James Cole, our Senior Policy, Research and Influencing Manager, write about how disengagement in HIV care is a global issue driven by inequalities and intersecting forms of stigma and discrimination.

Daniel Fluskey, our Director of Policy, Research and Influencing, writes about how ensuring high quality, equitable, and sustainable HIV and sexual health services across the UK has to be the bedrock of public policy that aims to end HIV transmissions and support everyone to live well with HIV.

Deborah Gold writes how we’re delighted with the encouraging updates in the HIV Action Plan annual report, but must not lose sight of the challenges that still remain.

Winnie Sseruma writes that the game-changing HIV prevention drug PrEP is a vital tool to end new HIV transmissions. But a 2022 report showed that many who might benefit from PrEP were not currently able to access it, including women and those from racially minoritised communities.

Michelle, founder, Director of Holistic Wellbeing Services and training lead at CliniQ on why the barriers to PrEP access that are faced by trans people must be addressed.

This year marks 40 years since the start of the HIV epidemic in the UK. As we remember and celebrate the lives of those lost, we also mark the progress made over this time.

Dr Tristan Barber writes that when patients are asked if they’ve ever had an HIV test many respond their GP did blood tests and they’re sure HIV must’ve been checked then. Most often they are incorrect.

Last year we welcomed the publication of the first report of Dame Carole Black’s independent review of drugs. Part two of the review, looking at prevention, treatment and recovery, was published last week.

People born abroad in the UK are disproportionally affected by HIV but up until now, there has been no shared understanding of the policies and interventions needed to combat HIV in the context of migration.